Paper - WANFANG MED ONLINE

You Position: Home > Paper

Determination of imatinib in human plasma and its significance

( views:623, downloads:152 )

Author:: No author available

Journal Title:: JOURNAL OF LEUKEMIA & LYMPHOMA

Issue:: 1

DOI:: 10.3760/cma.j.issn.1009-9921.2010.01.025

Key Word:: 伊马替尼;血药浓度;意义;Imatinib;Concentration;Significance

Abstract： As the first line of therapy for chronic myeloid leukemia, the outcome of imatinib is encouraging. The plasma concentration of imatinib is correlated with remission rate and survival, and affected by α1 acid glycoprotein(AGP) and those drugs which will change the activities of cytochrome P450(CYP3A4). It is conductive for the treatment of CML by monitoring the plasma concentration of imatinib.

Reference

[1]Rosselet A,Debiec-Rychter M,Biollaz J,etc.Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.[J].2008,98(10).
[2]B J, Druker,C L, Sawyers,R, Capdeville,etc.Chronic myelogenous leukemia.[J].2001.
[3]E. Schleyer,S. Pursche,C. H. Kohne,etc.Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations[J].2004,799(1).
[4]M W, Deininger,J M, Goldman,N, Lydon,etc.The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.[J].1997,90.
[5]Molimard M.Quantification of Imatinib in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry.[J].2005,27(5).
[6]Chollet C,Preudhomme C,Praloran V,etc.Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.[J].2006,91(2).
[7]Peng B,Lloyd P,Schran H.Clinical pharmacokinetics of imatinib.[J].2005,44(9).
[8]Druker BJ,Talpaz M,Resta DJ,etc.Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.[J].2001,344(14).
[9]Michele, Bianchini,Carlos, De Brasi,Patricia, Gargallo,etc.Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.[J].2009,82(4).
[10]Taksin AL,Mahon FX,Leguay T,etc.Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec((R))) in vitro and in vivo.[J].2003,66(10).
[11]Pane F,Specchia G,Castagnetti F,etc.The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.[J].2009,94(2).
[12]Mani S,Egorin MJ,Mulkerin DL,etc.Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.[J].2008,26(4).
[13]Bakhtiar R,Hayes M,Bedman T,etc.Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry.[J].2002,28(6).
[14]Philipp, le Coutre,Karl-Anton, Kreuzer,Il-Kang, Na,etc.Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.[J].1900,28.
[15]Rajani Mathur,Thirumurthy Velpandian,Nitin K. Agarwal,etc.Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples[J].2004,804(2).
[16]Mone M,Rudoltz M,Larson RA,etc.Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.[J].2009,115(3).
[17]Deininger MW,Druker BJ.Specific targeted therapy of chronic myelogenous leukemia with imatinib.[J].2003,55(3).
[18]M. Medenica,B. Jancic,D. Ivanovic,etc.Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec capsules[J].2004,800(1).
[19]Sekhar NM,Sreenivas Rao D,Vivekanand VV,etc.A validated LC method for imatinib mesylate.[J].2003,33(5).
[20]Tellingen O,Schellens JH,Beijnen JH,etc.Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.[J].2007,21(7).
[21]L. A. Decosterd,B. Rochat,A. Rosselet,etc.Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection[J].2004,803(2).
[22]Krahnke T,Cortes J,Sawyers C,etc.Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.[J].2008,111(3).
[23]Krahnke T,Gathmann I,Wang Y,etc.Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.[J].2008,111(8).
[24]Kantarjian H,Powell BL,Cervantes F,etc.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.[J].2006,355(23).